---
title: "Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285375039.md"
description: "Allarity Therapeutics announced that the manufacturing of the active pharmaceutical ingredient (API) for stenoparib is on schedule for completion by Q3 2026. The Phase 3 manufacturing campaign is progressing as planned, with all payments completed and no further cash outlays expected. The manufacturing is being conducted at a European CDMO that meets FDA and EMA GMP standards, ensuring a high-quality API is available ahead of critical Phase 2 data and potential pivotal trials."
datetime: "2026-05-06T12:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285375039.md)
  - [en](https://longbridge.com/en/news/285375039.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285375039.md)
---

# Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion

**Allarity Therapeutics reported that the active pharmaceutical ingredient manufacturing campaign for stenoparib is on track for completion no later than Q3 2026.**

**Key Highlights:**

-   API Phase 3 manufacturing campaign progressing per plan, expected completed by Q3 2026 to support pivotal development.
-   Manufacturing at a European CDMO compliant with FDA and EMA GMP standards for late-stage clinical supply.
-   All manufacturing-related payments completed; no additional cash outlays for manufacturing anticipated.
-   Completion timed to ensure higher-standard API is available ahead of anticipated critical Phase 2 data and potential pivotal trial.

Original SEC Filing: Allarity Therapeutics, Inc. \[ ALLR \] - 8-K - May. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Allarity Therapeutics Q1 net loss per share narrows](https://longbridge.com/en/news/286612460.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)